| Previous Close | 33.32 |
| Open | 33.38 |
| Bid | 33.36 x 2200 |
| Ask | 33.37 x 1600 |
| Day's Range | 33.24 - 33.48 |
| 52 Week Range | 29.83 - 37.39 |
| Volume | 1,431,431 |
| Avg. Volume | 20,314,514 |
| Market Cap | 198.61B |
| Beta | 1.07 |
| PE Ratio (TTM) | 28.01 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 1.28 (3.82%) |
| Ex-Dividend Date | 2017-08-02 |
| 1y Target Est | N/A |
- Market Realist•43 minutes ago
How Pfizer’s Vaccine Franchise Is Positioned in 2017
In 2016, Pfizer’s (PFE) Prevnar 13 reported revenues of ~$5.7 billion, which reflected a ~8% decline on a YoY (year-over-year) basis.
- Market Realist•2 hours ago
Why Xeljanz Could Boost Pfizer’s Revenue Growth
In 2016, Pfizer’s (PFE) Xeljanz reported revenues of ~$927 million, which reflected a ~77% growth YoY (year-over-year).
- Market Realist•2 hours ago
Analysts’ Recommendations for Merck in July 2017
Twenty-two analysts covered Merck in July 2017. Four analysts recommended a “strong buy” while ten analysts recommended a “buy.”
